Investigating how myofibroblasts contribute to lung scarring in pulmonary fibrosis
Official title: E-Box Accessibility in Myofibroblasts in Pulmonary Fibrosis
Funded at University of Pittsburgh at Pittsburgh · NIH-11049284 · Data updated 2026-11-12
This study is looking at how certain cells in the lungs, called myofibroblasts, behave in people with idiopathic pulmonary fibrosis (IPF) to help find new ways to treat this lung disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | January 1, 2025 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $773,440 |
| NIH project number | 1R01HL173817-01A1 |
| Project ID | NIH-11049284 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis.
✕Less likely to help
Patients with other forms of lung disease or those without a diagnosis of pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on understanding the role of myofibroblasts in idiopathic pulmonary fibrosis (IPF), a serious lung condition that leads to scarring and respiratory failure. By using advanced techniques like single nucleus assay for transposase-accessible chromatin sequencing, the researchers aim to uncover how specific genetic elements, particularly E-Box motifs, regulate the behavior of myofibroblasts in the lungs of patients with IPF. This study will provide insights into the molecular mechanisms driving lung fibrosis, potentially leading to new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that target the mechanisms of lung scarring in pulmonary fibrosis, improving patient outcomes.
How similar studies have gone: Previous research has shown promising results in understanding the role of myofibroblasts in lung diseases, making this approach both relevant and potentially impactful.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Kass, Daniel J — University of Pittsburgh at Pittsburgh
- Study coordinator: Kass, Daniel J
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.